- call +1-201-465-4211
- email sales@mrinsights.biz
Prostate cancer is cancer that occurs in the prostate.
Scope of the Report:
This report studies the Prostate Cancer market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Prostate Cancer market by product type and applications/end industries.
The global Prostate Cancer market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Prostate Cancer.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Astellas, Inc.
AstraZeneca plc
Johnson & Johnson
Sanofi S.A
Bristol Myers Squibb (BMS)
Bayer AG
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Hormone sensitive prostate cancer
Hormone refractory prostate cancer
Market Segment by Applications, can be divided into
Chemotherapy
Hormonal Therapy
Targeted Therapy
Immunotherapy
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Prostate Cancer Market Overview
1.1 Product Overview and Scope of Prostate Cancer
1.2 Classification of Prostate Cancer by Types
1.2.1 Global Prostate Cancer Revenue Comparison by Types (2017-2023)
1.2.2 Global Prostate Cancer Revenue Market Share by Types in 2017
1.2.3 Hormone sensitive prostate cancer
1.2.4 Hormone refractory prostate cancer
1.3 Global Prostate Cancer Market by Application
1.3.1 Global Prostate Cancer Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Chemotherapy
1.3.3 Hormonal Therapy
1.3.4 Targeted Therapy
1.3.5 Immunotherapy
1.4 Global Prostate Cancer Market by Regions
1.4.1 Global Prostate Cancer Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Prostate Cancer Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Prostate Cancer Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Prostate Cancer Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Prostate Cancer Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Prostate Cancer Status and Prospect (2013-2023)
1.5 Global Market Size of Prostate Cancer (2013-2023)
2 Manufacturers Profiles
2.1 Astellas, Inc.
2.1.1 Business Overview
2.1.2 Prostate Cancer Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Astellas, Inc. Prostate Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.2 AstraZeneca plc
2.2.1 Business Overview
2.2.2 Prostate Cancer Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AstraZeneca plc Prostate Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.3 Johnson & Johnson
2.3.1 Business Overview
2.3.2 Prostate Cancer Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Johnson & Johnson Prostate Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.4 Sanofi S.A
2.4.1 Business Overview
2.4.2 Prostate Cancer Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sanofi S.A Prostate Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol Myers Squibb (BMS)
2.5.1 Business Overview
2.5.2 Prostate Cancer Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bristol Myers Squibb (BMS) Prostate Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.6 Bayer AG
2.6.1 Business Overview
2.6.2 Prostate Cancer Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Bayer AG Prostate Cancer Revenue, Gross Margin and Market Share (2016-2017)
3 Global Prostate Cancer Market Competition, by Players
3.1 Global Prostate Cancer Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Prostate Cancer Players Market Share
3.2.2 Top 10 Prostate Cancer Players Market Share
3.3 Market Competition Trend
4 Global Prostate Cancer Market Size by Regions
4.1 Global Prostate Cancer Revenue and Market Share by Regions
4.2 North America Prostate Cancer Revenue and Growth Rate (2013-2018)
4.3 Europe Prostate Cancer Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Prostate Cancer Revenue and Growth Rate (2013-2018)
4.5 South America Prostate Cancer Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Prostate Cancer Revenue and Growth Rate (2013-2018)
5 North America Prostate Cancer Revenue by Countries
5.1 North America Prostate Cancer Revenue by Countries (2013-2018)
5.2 USA Prostate Cancer Revenue and Growth Rate (2013-2018)
5.3 Canada Prostate Cancer Revenue and Growth Rate (2013-2018)
5.4 Mexico Prostate Cancer Revenue and Growth Rate (2013-2018)
6 Europe Prostate Cancer Revenue by Countries
6.1 Europe Prostate Cancer Revenue by Countries (2013-2018)
6.2 Germany Prostate Cancer Revenue and Growth Rate (2013-2018)
6.3 UK Prostate Cancer Revenue and Growth Rate (2013-2018)
6.4 France Prostate Cancer Revenue and Growth Rate (2013-2018)
6.5 Russia Prostate Cancer Revenue and Growth Rate (2013-2018)
6.6 Italy Prostate Cancer Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Prostate Cancer Revenue by Countries
7.1 Asia-Pacific Prostate Cancer Revenue by Countries (2013-2018)
7.2 China Prostate Cancer Revenue and Growth Rate (2013-2018)
7.3 Japan Prostate Cancer Revenue and Growth Rate (2013-2018)
7.4 Korea Prostate Cancer Revenue and Growth Rate (2013-2018)
7.5 India Prostate Cancer Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Prostate Cancer Revenue and Growth Rate (2013-2018)
8 South America Prostate Cancer Revenue by Countries
8.1 South America Prostate Cancer Revenue by Countries (2013-2018)
8.2 Brazil Prostate Cancer Revenue and Growth Rate (2013-2018)
8.3 Argentina Prostate Cancer Revenue and Growth Rate (2013-2018)
8.4 Colombia Prostate Cancer Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Prostate Cancer by Countries
9.1 Middle East and Africa Prostate Cancer Revenue by Countries (2013-2018)
9.2 Saudi Arabia Prostate Cancer Revenue and Growth Rate (2013-2018)
9.3 UAE Prostate Cancer Revenue and Growth Rate (2013-2018)
9.4 Egypt Prostate Cancer Revenue and Growth Rate (2013-2018)
9.5 Nigeria Prostate Cancer Revenue and Growth Rate (2013-2018)
9.6 South Africa Prostate Cancer Revenue and Growth Rate (2013-2018)
10 Global Prostate Cancer Market Segment by Type
10.1 Global Prostate Cancer Revenue and Market Share by Type (2013-2018)
10.2 Global Prostate Cancer Market Forecast by Type (2018-2023)
10.3 Hormone sensitive prostate cancer Revenue Growth Rate (2013-2023)
10.4 Hormone refractory prostate cancer Revenue Growth Rate (2013-2023)
11 Global Prostate Cancer Market Segment by Application
11.1 Global Prostate Cancer Revenue Market Share by Application (2013-2018)
11.2 Prostate Cancer Market Forecast by Application (2018-2023)
11.3 Chemotherapy Revenue Growth (2013-2018)
11.4 Hormonal Therapy Revenue Growth (2013-2018)
11.5 Targeted Therapy Revenue Growth (2013-2018)
11.6 Immunotherapy Revenue Growth (2013-2018)
12 Global Prostate Cancer Market Size Forecast (2018-2023)
12.1 Global Prostate Cancer Market Size Forecast (2018-2023)
12.2 Global Prostate Cancer Market Forecast by Regions (2018-2023)
12.3 North America Prostate Cancer Revenue Market Forecast (2018-2023)
12.4 Europe Prostate Cancer Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Prostate Cancer Revenue Market Forecast (2018-2023)
12.6 South America Prostate Cancer Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Prostate Cancer Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Prostate Cancer Picture
Table Product Specifications of Prostate Cancer
Table Global Prostate Cancer and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
